SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Pictured: J&J's office in Madrid, Spain
Lung cancer
J&J Challenges AstraZeneca’s Tagrisso With Phase III Data for Rybrevant, Lazcluze Combo
Follow-up data from the MARIPOSA study show a favorable overall survival trend versus Tagrisso in EGFR-mutated advanced non-small cell lung cancer. The findings come just weeks after the Rybrevant-Lazcluze combination was approved for the first-line treatment.
September 9, 2024
 · 
2 min read
 · 
Tristan Manalac
Facade of AstraZeneca's office in Shanghai, China
Antibody-drug conjugate (ADC)
AstraZeneca, Daiichi Sankyo Turn to AI to Explain Phase III NSCLC Miss for Dato-DXd
Using a computational biomarker, the companies say they can identify which patients would derive significant clinical benefit from their experimental antibody-drug conjugate. AstraZeneca and Roche are co-developing and commercializing a companion diagnostic for the biomarker.
September 9, 2024
 · 
2 min read
 · 
Tristan Manalac
GSK's headquarters in West London
Immunology and inflammation
GSK Builds Nucala’s COPD Case With Phase III Win
If approved in chronic obstructive pulmonary disease, Nucala will compete with Verona’s Ohtuvayre and—pending a potential approval later this month—Sanofi and Regeneron’s blockbuster Dupixent.
September 6, 2024
 · 
2 min read
 · 
Tristan Manalac
rear view businesswoman standing on wooden pier and looking to sea business and challenge crisis bankruptcy concept horizontal full length vector illustration
People
Lykos CEO to Resign After FDA Rejection of MDMA Therapy, Layoffs
Amy Emerson is stepping down on the heels of the FDA last month rejecting Lykos Therapeutics’ MDMA-based therapy for post-traumatic stress disorder and the company laying off three-quarters of its staff.
September 6, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: FDA signage at its office in Washington, DC
Approvals
Travere Wins Full FDA Approval for IgAN Treatment Filspari
With the regulator’s traditional green light in IgA nephropathy, Filspari is up against Novartis’ Fabhalta—which won accelerated approval last month—and Calliditas’ Tarpeyo, which was approved in December 2023.
September 6, 2024
 · 
2 min read
 · 
Tristan Manalac
Cigna Healthcare office in Delaware
Pharmacy benefit managers
Cigna Continues Biosimilar Push, Targets J&J’s Stelara With No Out-of-Pocket Cost
Thursday’s announcement comes after the insurance giant last week said it would remove AbbVie’s Humira from its major formularies starting in 2025, replacing the blockbuster with more affordable biosimilars.
September 6, 2024
 · 
2 min read
 · 
Tristan Manalac
Eli Lilly's world headquarters in Indianapolis
Diabetes
Lilly Gains Ground on Novo With Positive Phase III Readouts for Weekly Insulin
Eli Lilly’s weekly insulin injection efsitora alfa secured two late-stage victories on Thursday in a potential blow to rival Novo Nordisk, which in July failed to secure the FDA’s approval for its basal insulin icodec.
September 5, 2024
 · 
2 min read
 · 
Tristan Manalac
Amgen sign at its headquarters in Thousand Oaks, California, USA.
Obesity
Amgen Plans Phase III Program for Next-Gen Obesity Drug Targeting Liver and Kidney Diseases
A broad indication for MariTide could help Amgen secure Medicare coverage for the treatment following FDA approval, CEO Robert Bradway said at Wednesday’s Morgan Stanley Global Healthcare Conference.
September 5, 2024
 · 
2 min read
 · 
Tristan Manalac
3D illustration of tow GLP-1 therapy autoinjectors
GLP-1
UK’s MHRA Finds No Risk of Suicidal Ideation, Self-Harm With GLP-1 Drugs
Like its U.S. and European counterparts, Britain’s Medicines and Healthcare Products Regulatory Agency found no conclusive link between the use of GLP-1s and a heightened risk of suicidal and self-injury thoughts.
September 5, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Novartis' logo outside its building in S
Manufacturing
Novartis Starts Construction on Two US Sites to Bolster Radioligand Therapy Manufacturing
The company is building a new facility in California, its third U.S.-based radioligand therapy production site, and expanding an Indianapolis site for producing isotopes for cancer treatment.
September 5, 2024
 · 
2 min read
 · 
Tristan Manalac
Roche's signage at its office in France
Multiple sclerosis
Roche Touts Phase II MS Data on Heels of Sanofi’s Late-Stage Stumbles
Days after Sanofi reported back-to-back failures for its BTK inhibitor, Roche’s fenebrutinib on Wednesday scored a mid-stage win in relapsing multiple sclerosis, demonstrating near-total elimination of disease activity.
September 4, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Nasdaq headquarters in New York/iStock,
IPO
Lilly Partner BioAge Files for IPO to Advance Obesity Candidate
BioAge will use the proceeds from the initial public offering to move its oral apelin receptor agonist azelaprag past its Phase III STRIDES study and into a registrational Phase III trial.
September 4, 2024
 · 
2 min read
 · 
Tristan Manalac
3D illustration of neurons
Alzheimer’s disease
Athira’s Small Molecule Injection for Alzheimer’s Flops in Phase II/III Study
The investigational injection fosgonimeton appeared to have better efficacy in patients with more severe disease, according to post-hoc subgroup analyses, though none resulted in statistically significant effects.
September 4, 2024
 · 
2 min read
 · 
Tristan Manalac
MRI scans of a human brain
Neuroscience
Recursion Reports Thin Mid-Stage Efficacy Data for Rare Brain Disease Therapy
Recursion’s oral drug candidate for cerebral cavernous malformation showed no improvements in patient- or physician-reported outcomes at 12 months. The biotech will engage with the FDA to determine the need for an additional study.
September 4, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Boy in a wheelchair looking out the window
Duchenne muscular dystrophy
Dyne Touts ‘Unprecedented’ Dystrophin Expression in Phase I/II DMD Trial for Exon-Skipping Therapy
The highly anticipated results come as the company makes significant changes to its C-suite. Despite the turnover, Dyne said it is looking toward expedited approval pathways for its DMD treatment.
September 3, 2024
 · 
3 min read
 · 
Tristan Manalac
Load More